Literature DB >> 23011030

Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines.

Charlotte Pollard1, Joanna Rejman, Winni De Haes, Bernard Verrier, Ellen Van Gulck, Thomas Naessens, Stefaan De Smedt, Pieter Bogaert, Johan Grooten, Guido Vanham, Stefaan De Koker.   

Abstract

The use of DNA and viral vector-based vaccines for the induction of cellular immune responses is increasingly gaining interest. However, concerns have been raised regarding the safety of these immunization strategies. Due to the lack of their genome integration, mRNA-based vaccines have emerged as a promising alternative. In this study, we evaluated the potency of antigen-encoding mRNA complexed with the cationic lipid 1,2-dioleoyl-3trimethylammonium-propane/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOTAP/DOPE ) as a novel vaccination approach. We demonstrate that subcutaneous immunization of mice with mRNA encoding the HIV-1 antigen Gag complexed with DOTAP/DOPE elicits antigen-specific, functional T cell responses resulting in specific killing of Gag peptide-pulsed cells and the induction of humoral responses. In addition, we show that DOTAP/DOPE complexed antigen-encoding mRNA displays immune-activating properties characterized by secretion of type I interferon (IFN) and the recruitment of proinflammatory monocytes to the draining lymph nodes. Finally, we demonstrate that type I IFN inhibit the expression of DOTAP/DOPE complexed antigen-encoding mRNA and the subsequent induction of antigen-specific immune responses. These results are of high relevance as they will stimulate the design and development of improved mRNA-based vaccination approaches.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23011030      PMCID: PMC3538310          DOI: 10.1038/mt.2012.202

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  33 in total

1.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.

Authors:  Katalin Karikó; Michael Buckstein; Houping Ni; Drew Weissman
Journal:  Immunity       Date:  2005-08       Impact factor: 31.745

Review 2.  The perfect mix: recent progress in adjuvant research.

Authors:  Bruno Guy
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

3.  Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection.

Authors:  Colin Havenar-Daughton; Ganesh A Kolumam; Kaja Murali-Krishna
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

4.  Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA.

Authors:  Birgit Scheel; Steffen Aulwurm; Jochen Probst; Lothar Stitz; Ingmar Hoerr; Hans-Georg Rammensee; Michael Weller; Steve Pascolo
Journal:  Eur J Immunol       Date:  2006-10       Impact factor: 5.532

5.  Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins.

Authors:  Ellen R A Van Gulck; Peter Ponsaerts; Leo Heyndrickx; Katleen Vereecken; Filip Moerman; Ann De Roo; Robert Colebunders; Glenn Van den Bosch; Dirk R Van Bockstaele; Viggo F I Van Tendeloo; Sabine Allard; Bernard Verrier; Concepción Marañón; Guillaume Hoeffel; Anne Hosmalin; Zwi N Berneman; Guido Vanham
Journal:  Blood       Date:  2005-11-01       Impact factor: 22.113

6.  Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming.

Authors:  Agnes Le Bon; Vanessa Durand; Elisabeth Kamphuis; Clare Thompson; Silvia Bulfone-Paus; Cornelia Rossmann; Ulrich Kalinke; David F Tough
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

Review 7.  Vaccination with messenger RNA (mRNA).

Authors:  Steve Pascolo
Journal:  Handb Exp Pharmacol       Date:  2008

8.  Characterization of a messenger RNA polynucleotide vaccine vector.

Authors:  R M Conry; A F LoBuglio; M Wright; L Sumerel; M J Pike; F Johanning; R Benjamin; D Lu; D T Curiel
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

9.  Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection.

Authors:  Ganesh A Kolumam; Sunil Thomas; Lucas J Thompson; Jonathan Sprent; Kaja Murali-Krishna
Journal:  J Exp Med       Date:  2005-08-29       Impact factor: 14.307

10.  Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells.

Authors:  V Brinkmann; T Geiger; S Alkan; C H Heusser
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

View more
  74 in total

Review 1.  mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors:  Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-02-07       Impact factor: 11.454

2.  Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design.

Authors:  Timothy Pepini; Anne-Marie Pulichino; Thomas Carsillo; Alicia L Carlson; Farid Sari-Sarraf; Katrin Ramsauer; Jason C Debasitis; Giulietta Maruggi; Gillis R Otten; Andrew J Geall; Dong Yu; Jeffrey B Ulmer; Carlo Iavarone
Journal:  J Immunol       Date:  2017-04-17       Impact factor: 5.422

Review 3.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

4.  RNA-based vaccination: sending a strong message.

Authors:  David B Weiner
Journal:  Mol Ther       Date:  2013-03       Impact factor: 11.454

5.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy.

Authors:  Matthias A Oberli; Andreas M Reichmuth; J Robert Dorkin; Michael J Mitchell; Owen S Fenton; Ana Jaklenec; Daniel G Anderson; Robert Langer; Daniel Blankschtein
Journal:  Nano Lett       Date:  2016-12-05       Impact factor: 11.189

6.  A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

Authors:  Luis A Brito; Michelle Chan; Christine A Shaw; Armin Hekele; Thomas Carsillo; Mary Schaefer; Jacob Archer; Anja Seubert; Gillis R Otten; Clayton W Beard; Antu K Dey; Anders Lilja; Nicholas M Valiante; Peter W Mason; Christian W Mandl; Susan W Barnett; Philip R Dormitzer; Jeffrey B Ulmer; Manmohan Singh; Derek T O'Hagan; Andrew J Geall
Journal:  Mol Ther       Date:  2014-07-16       Impact factor: 11.454

Review 7.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 8.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Authors:  Karl-Josef Kallen; Andreas Theß
Journal:  Ther Adv Vaccines       Date:  2014-01

Review 9.  mRNA vaccine delivery using lipid nanoparticles.

Authors:  Andreas M Reichmuth; Matthias A Oberli; Ana Jaklenec; Robert Langer; Daniel Blankschtein
Journal:  Ther Deliv       Date:  2016

10.  Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.

Authors:  Michela Brazzoli; Diletta Magini; Alessandra Bonci; Scilla Buccato; Cinzia Giovani; Roland Kratzer; Vanessa Zurli; Simona Mangiavacchi; Daniele Casini; Luis M Brito; Ennio De Gregorio; Peter W Mason; Jeffrey B Ulmer; Andrew J Geall; Sylvie Bertholet
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.